{"id":30869,"date":"2023-07-03T13:25:21","date_gmt":"2023-07-03T17:25:21","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/astrazeneca-shares-slump-after-phase-3-lung-cancer-drug-study\/"},"modified":"2023-07-03T13:25:23","modified_gmt":"2023-07-03T17:25:23","slug":"astrazeneca-shares-slump-after-phase-3-lung-cancer-drug-study","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=30869","title":{"rendered":"AstraZeneca shares slump after Phase 3 lung cancer drug study"},"content":{"rendered":"
\n

AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors.<\/p>\n

AstraZeneca\u2019s
\n AZN,
\n -8.83%<\/bg-quote><\/p>\n

AZN,
\n -8.00%<\/bg-quote>
\n shares slumped as much as 6% as the U.K. drugmaker said\u00a0its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial. <\/p>\n

\n

That sounds good, but there were important caveats for a drug that some analysts say has the potential for peak sales of over $10 billion. AstraZeneca said the trial will continue to assess the dual primary endpoint of overall survival as the data \u201cwere not mature\u201d and did not meet the prespecified threshold for statistical significance at this interim analysis.\u00a0<\/p>\n

Analysts at UBS also pointed out the company did not quantify the progression-free benefit, which it usually does. <\/p>\n

Analysts at Shore Capital said the company had previously outlined that a two- to three-month improvement in progression-free survival versus docetaxel would be needed for the result to be considered clinically meaningful.<\/p>\n

AstraZeneca and Daiichi Sankyo
\n 4568,
\n +0.62%<\/bg-quote>
\n are jointly developing and commercializing datopotamab deruxtecan.<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped as much as 6% as the U.K. drugmaker said\u00a0its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial. That sounds good, but […]<\/p>\n","protected":false},"author":1,"featured_media":30870,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-30869","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nAstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld<\/title>\n<meta name=\"description\" content=\"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=30869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=30869\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-03T17:25:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-03T17:25:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/1688405122_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=30869#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=30869\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"AstraZeneca shares slump after Phase 3 lung cancer drug study\",\"datePublished\":\"2023-07-03T17:25:21+00:00\",\"dateModified\":\"2023-07-03T17:25:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=30869\"},\"wordCount\":186,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=30869#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=30869\",\"url\":\"https:\/\/ifintechworld.com\/?p=30869\",\"name\":\"AstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-07-03T17:25:21+00:00\",\"dateModified\":\"2023-07-03T17:25:23+00:00\",\"description\":\"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=30869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=30869\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=30869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca shares slump after Phase 3 lung cancer drug study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld","description":"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=30869","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld","og_description":"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped","og_url":"https:\/\/ifintechworld.com\/?p=30869","og_site_name":"iFintechWorld","article_published_time":"2023-07-03T17:25:21+00:00","article_modified_time":"2023-07-03T17:25:23+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/1688405122_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=30869#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=30869"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"AstraZeneca shares slump after Phase 3 lung cancer drug study","datePublished":"2023-07-03T17:25:21+00:00","dateModified":"2023-07-03T17:25:23+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=30869"},"wordCount":186,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=30869#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=30869","url":"https:\/\/ifintechworld.com\/?p=30869","name":"AstraZeneca shares slump after Phase 3 lung cancer drug study | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-07-03T17:25:21+00:00","dateModified":"2023-07-03T17:25:23+00:00","description":"AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors. AstraZeneca\u2019s AZN, -8.83% AZN, -8.00% shares slumped","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=30869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=30869"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=30869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca shares slump after Phase 3 lung cancer drug study"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/30869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30869"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/30869\/revisions"}],"predecessor-version":[{"id":30871,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/30869\/revisions\/30871"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/30870"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}